Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Fritz Heese

Partner, Health and Life Sciences, Oliver Wyman

Future Truths: Inevitable and Inspiring

Harnessing genomics will transform our daily lives, disrupt payer, provider, and pharma business models, and create new markets for next-generation prevention.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Principal, Oliver Wyman
Associate, Health and Life Sciences, Oliver Wyman

The distribution of COVID-19 vaccines like Moderna, Pfizer, and others demands immediate supply chain analysis and preparation.

Partner, Oliver Wyman
Partner, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Success awaits innovators that leverage pharma in a newly digitized world.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Software-only products providing free-standing treatment represent a key healthcare opportunity for incumbents.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Three CEOs discuss why digital treatments are on the cusp of becoming mainstream and share their five-year outlooks.

Partner, Health and Life Sciences, Oliver Wyman
Executive Chairman, President and CEO, Click Therapeutics
Former CEO, SyncThink
CEO, AbleTo

Insights in your inbox

Subscribe

Five workstreams to help leaders adopt a new organizational approach.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Head Leadership and Organizational Performance, Mercer

It's time to get comfortable with being uncomfortable.

Partner, Health and Life Sciences, Oliver Wyman

Innovator-Led Innovations May Soon Come True

Healthcare leaders demand disruption, but who will spark big change first?

President and CEO, Business Group on Health
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health and Life Sciences, Oliver Wyman
Senior Knowledge Expert, Oliver Wyman

Seeing a return on investment in pharma marketing means understanding what happens to every dollar.

Principal, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Digital & Analytics, Oliver Wyman

Insights in your inbox

Subscribe